Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

by Raskin, Jo , Conte, Pierfranco , Senellart, Helene , Han, Ji-Youn , Chen, Yuh-Min , Juraeva, Dilafruz , Cortot, Alexis B , Paik, Paul K , Bruns, Rolf , Scheele, Jürgen , Johne, Andreas , Chang, Gee-Chen , van der Wekken, Anthonie J , Reinmuth, Niels , Stroh, Christopher , Horn, Leora , Kowalski, Dariusz , Cho, Byoung Chul , Kim, Young-Chul , Van Meerbeeck, Jan , Griesinger, Frank , Smit, Egbert F , Felip, Enriqueta , Veillon, Remi , Yang, James C.-H , Straub, Josef , Viteri, Santiago , Kato, Terufumi , Patel, Jyoti D , Le, Xiuning , Sakai, Hiroshi , Heymach, John V , Garassino, Marina C , Mazieres, Julien , Tsai, Chen-Liang

in Adult / Aged / Aged, 80 and over / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Binding sites / Biopsy / Cancer / Carcinoma, Non-Small-Cell Lung - drug therapy / Carcinoma, Non-Small-Cell Lung - genetics / Edema / Edema - chemically induced / Enrollments / Exons / Female / Humans / Life Sciences / Lung cancer / Lung Neoplasms - drug therapy / Lung Neoplasms - genetics / Male / Metastases / Metastasis / Middle Aged / Mutation / Non-small cell lung carcinoma / Piperidines - adverse effects / Piperidines - therapeutic use / Population / Protein Kinase Inhibitors - adverse effects / Protein Kinase Inhibitors - therapeutic use / Proto-Oncogene Proteins c-met - antagonists & inhibitors / Proto-Oncogene Proteins c-met - genetics / Pyridazines - adverse effects / Pyridazines - therapeutic use / Pyrimidines - adverse effects / Pyrimidines - therapeutic use / Quality of life / Questionnaires / Small cell lung carcinoma / Transcription / Tumors

2020

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

2020

Confirm

Do you wish to request the book?

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

2020

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

Raskin, Jo,

Conte, Pierfranco,

Senellart, Helene,

Han, Ji-Youn,

Chen, Yuh-Min,

Juraeva, Dilafruz,

Cortot, Alexis B,

Paik, Paul K,

Bruns, Rolf,

Scheele, Jürgen,

Johne, Andreas,

Chang, Gee-Chen,

van der Wekken, Anthonie J,

Reinmuth, Niels,

Stroh, Christopher,

Horn, Leora,

Kowalski, Dariusz,

Cho, Byoung Chul,

Kim, Young-Chul,

Van Meerbeeck, Jan,

Griesinger, Frank,

Smit, Egbert F,

Felip, Enriqueta,

Veillon, Remi,

Yang, James C.-H,

Straub, Josef,

Viteri, Santiago,

Kato, Terufumi,

Patel, Jyoti D,

Le, Xiuning,

Sakai, Hiroshi,

Heymach, John V,

Garassino, Marina C,

Mazieres, Julien,

Tsai, Chen-Liang

2020

Overview

In a study involving patients with non–small-cell lung cancer with a MET exon 14 skipping mutation, the use of tepotinib (a selective MET inhibitor) was associated with a partial response in approximately half the patients. The main adverse event was peripheral edema.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Aged

/ Aged, 80 and over

/ Antineoplastic Agents - adverse effects

/ Antineoplastic Agents - therapeutic use

/ Binding sites

/ Biopsy